| Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value | 10/21 15:12 | seekingalpha.com |
| Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease | 10/18 09:16 | benzinga.com |
| Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial | 10/17 16:05 | globenewswire.com |
| 3 Small-Cap Stocks Ready to Deliver Significant Growth | 10/10 11:12 | marketbeat.com |
| Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + | 09/20 15:30 | seekingalpha.com |
| Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company | 09/17 12:31 | seekingalpha.com |
| Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study | 09/13 10:31 | zacks.com |
| Aura Biosciences Touts Promising Data From Eye Cancer Candidate | 09/12 11:40 | benzinga.com |
| Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma | 09/12 06:30 | globenewswire.com |
| Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 | 09/03 16:05 | globenewswire.com |